Literature DB >> 24095872

High-sensitivity analysis of buprenorphine, norbuprenorphine, buprenorphine glucuronide, and norbuprenorphine glucuronide in plasma and urine by liquid chromatography-mass spectrometry.

Karen J Regina1, Evan D Kharasch.   

Abstract

A new method using ultra-fast liquid chromatography and tandem mass spectrometry (UFLC-MS/MS) was developed for the simultaneous determination of buprenorphine and the metabolites norbuprenorphine, buprenorphine-3β-glucuronide, and norbuprenorphine-3β-glucuronide in plasma and urine. Sample handling, sample preparation and solid-phase extraction procedures were optimized for maximum analyte recovery. All four analytes of interest were quantified by positive ion electrospray ionization tandem mass spectrometry after solid-phase microextraction. The lower limits of quantification in plasma were 1pg/mL for buprenorphine and buprenorphine glucuronide, and 10pg/mL for norbuprenorphine and norbuprenorphine glucuronide. The lower limits of quantitation in urine were 10pg/mL for buprenorphine, norbuprenorphine and their glucuronides. Overall extraction recoveries ranged from 68-100% in both matrices. Interassay precision and accuracy was within 10% for all four analytes in plasma and within 15% in urine. The method was applicable to pharmacokinetic studies of low-dose buprenorphine.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Buprenorphine; Glucuronide; Mass spectrometry; Norbuprenorphine

Mesh:

Substances:

Year:  2013        PMID: 24095872      PMCID: PMC3936475          DOI: 10.1016/j.jchromb.2013.09.004

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  47 in total

1.  Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naïve healthy male volunteers under a naltrexone block.

Authors:  Sarah D McAleer; Richard J Mills; Torsten Polack; Tanweer Hussain; Paul E Rolan; Alan D Gibbs; Frank G P Mullins; Ziad Hussein
Journal:  Drug Alcohol Depend       Date:  2003-10-24       Impact factor: 4.492

Review 2.  Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence.

Authors:  Ali S Saber-Tehrani; Robert Douglas Bruce; Frederick L Altice
Journal:  Am J Drug Alcohol Abuse       Date:  2011-01       Impact factor: 3.829

3.  Gas chromatographic-mass spectrometric quantitation of urinary buprenorphine and norbuprenorphine after derivatization by direct extractive alkylation.

Authors:  A M Lisi; R Kazlauskas; G J Trout
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1997-04-25

4.  Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active.

Authors:  Sarah M Brown; Michael Holtzman; Thomas Kim; Evan D Kharasch
Journal:  Anesthesiology       Date:  2011-12       Impact factor: 7.892

5.  Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine.

Authors:  J J Kuhlman; S Lalani; J Magluilo; B Levine; W D Darwin
Journal:  J Anal Toxicol       Date:  1996-10       Impact factor: 3.367

6.  HPLC/MS determination of buprenorphine and norbuprenorphine in biological fluids and hair samples.

Authors:  A Tracqui; P Kintz; P Mangin
Journal:  J Forensic Sci       Date:  1997-01       Impact factor: 1.832

7.  Buprenorphine induces ceiling in respiratory depression but not in analgesia.

Authors:  A Dahan; A Yassen; R Romberg; E Sarton; L Teppema; E Olofsen; M Danhof
Journal:  Br J Anaesth       Date:  2006-03-17       Impact factor: 9.166

8.  Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study.

Authors:  Monica Escher; Youssef Daali; Jocelyne Chabert; Gérard Hopfgartner; Pierre Dayer; Jules Desmeules
Journal:  Clin Ther       Date:  2007-08       Impact factor: 3.393

9.  Rapid quantification of buprenorphine-glucuronide and norbuprenorphine-glucuronide in human urine by LC-MS-MS.

Authors:  S Hegstad; H Z Khiabani; E L Øiestad; T Berg; A S Christophersen
Journal:  J Anal Toxicol       Date:  2007-05       Impact factor: 3.367

10.  A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies.

Authors:  David E Moody; Matthew H Slawson; Eric C Strain; John D Laycock; Alan C Spanbauer; Rodger L Foltz
Journal:  Anal Biochem       Date:  2002-07-01       Impact factor: 3.365

View more
  2 in total

1.  Pharmacokinetics of intravenous, oral transmucosal, and intranasal buprenorphine in healthy male dogs.

Authors:  Hiroko Enomoto; Lydia Love; Melanie Madsen; Amber Wallace; Kristen M Messenger
Journal:  J Vet Pharmacol Ther       Date:  2022-04-21       Impact factor: 1.567

Review 2.  Pharmacokinetics of buprenorphine in pregnant sheep after intravenous injection.

Authors:  Henriikka Hakomäki; Hannu Kokki; Marko Lehtonen; Veli-Pekka Ranta; Juha Räsänen; Hanna-Marja Voipio; Merja Kokki
Journal:  Pharmacol Res Perspect       Date:  2021-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.